Skip to main content
. Author manuscript; available in PMC: 2021 Jan 20.
Published in final edited form as: Clin Pharmacol Ther. 2020 Jan 30;107(6):1383–1393. doi: 10.1002/cpt.1751

Table 1.

Description of the four data sets and patient demographics. Number of samples from each study utilized in the combined analysis following removal of individuals with non-European genetic ancestry, sex mismatches, and related samples within and between data sets

Data sets
1 2 3 4
N 145 161 322 555
Sex
 Male 68 (46.9%) 105 (65.2%) 150 (46.6%) 152 (27.4%)
 Female 77 (53.1%) 56 (34.8%) 172 (53.4%) 403 (72.6%)
Age (years)
 ≤ 1 0 (0%) 2 (1.2%) 1 (0.3%) 0 (0%)
 2–19 2 (1.4%) 35 (21.7%) 12 (3.7%) 5 (0.9%)
 20–59 76 (52.4%) 81 (50.3%) 198 (61.5%) 496 (89.4%)
 > 59 67 (46.2%) 43 (26.7%) 111 (34.5%) 54 (9.7%)
 Mean (range) 58.3 (7–85) 41.4 (1–81) 50.9 (0–94.3) 45.5 (18–75)
Genotyping Illumina HumanHap300-Duo v2.0 (GEO: GSE39036) Illumina Human610-Quad v1.0 (GEO: GSE26105) Affymetrix GeneChip Human Mapping 500K HumanHap 650Y
Expression microarray Illumina Human Whole Genome-6 v2.0 (GEO: GSE32504) Agilent-014850 Whole Human Genome 4x44K (GEO: GSE25935) Agilent Technologies (Custom ~40K transcripts) (GEO: GSE9588) Agilent Technologies (Custom ~40K transcripts) (GEO: GSE24293)